Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

Global Markets Direct
2236 Pages - GMD17106
$2,500.00

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3-V Biosciences Inc
3SBio Inc
4SC AG
AbbVie Inc
Ability Pharmaceuticals SL
ACEA Biosciences Inc
Acetylon Pharmaceuticals Inc
Adamed Sp z oo
Adaptimmune Therapeutics Plc
Advanced Cancer Therapeutics
Advantagene Inc
Advenchen Laboratories LLC
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Altimmune Inc
Altor BioScience Corp
Amgen Inc
Andarix Pharmaceuticals Inc
AndroScience Corp
Apac Biotech Pvt Ltd
APO-T BV
Aptevo Therapeutics Inc
Aptose Biosciences Inc
Argos Therapeutics Inc
Ariad Pharmaceuticals Inc
ARMO Biosciences Inc
Arog Pharmaceuticals Inc
ArQule Inc
Array BioPharma Inc
Arrien Pharmaceuticals LLC
Asana BioSciences LLC
Astellas Pharma Inc
Asterias Biotherapeutics Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
ATLAB Pharma SAS
Atreca Inc
Aurigene Discovery Technologies Ltd
AVEO Pharmaceuticals Inc
Axelar AB
Azaya Therapeutics Inc
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
BerGenBio AS
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Pharmaceuticals Inc
Bio-Path Holdings Inc
Biocad
BioCancell Ltd
Biocon Ltd
BioLineRx Ltd
Bionovis SA
Biothera Pharmaceutical Inc
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
CanBas Co Ltd
Cantargia AB
CASI Pharmaceuticals Inc
CBT Pharmaceuticals Inc
Celgene Corp
CellAct Pharma GmbH
Cellceutix Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellmid Ltd
Cellular Biomedicine Group Inc
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co Ltd
Cielo Therapeutics Inc
Cipla Ltd
Cleave Biosciences Inc
Coherus BioSciences Inc
Corcept Therapeutics Inc
Cornerstone Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Critical Outcome Technologies Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
CytImmune Sciences Inc
CytomX Therapeutics Inc
CytRx Corp
Daiichi Sankyo Company Ltd
DanDrit Biotech A/S
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Denovo Biopharma LLC
DiNonA Inc
Domainex Ltd
DormaTarg Inc
Double Bond Pharmaceutical International AB
Dr. Reddy's Laboratories Ltd
Eagle Pharmaceuticals Inc
EirGenix Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Endocyte Inc
EnGeneIC Ltd
EntreChem SL
Enumeral Biomedical Holdings Inc
Eudendron Srl
Evotec AG
Exelixis Inc
F. Hoffmann-La Roche Ltd
FibroStatin SL
Five Prime Therapeutics Inc
Fujifilm Corp
G&E Herbal Biotechnology Co Ltd
Ganymed Pharmaceuticals AG
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genmab A/S
Genocea Biosciences Inc
Genor BioPharma Co Ltd
Genosco Inc
Genzyme Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Globeimmune Inc
GlycaNova Norway AS
Glycotope GmbH
Golden Biotechnology Corp
Gradalis Inc
Grunenthal GmbH
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
HEC Pharm Co Ltd
Helix BioPharma Corp
Hemispherx Biopharma Inc
Heptares Therapeutics Ltd
HitGen LTD
Horizon Pharma Plc
Hutchison MediPharma Ltd
iCeutica Inc
Ideaya Biosciences Inc
Ignyta Inc
Immune Design Corp
Immune Pharmaceuticals Inc
ImmunGene Inc
Immunocore Ltd
ImmunoGen Inc
Immunome Inc
Immunomedics Inc
Incuron LLC
Incyte Corp
Infinity Pharmaceuticals Inc
Inflection Biosciences Ltd
Innovent Biologics Inc
Inovio Pharmaceuticals Inc
Intas Pharmaceuticals Ltd
Invectys SA
Inventiva
IO Biotech ApS
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
JHL Biotech Inc
Jiangsu Hansoh Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Juno Therapeutics Inc
Kadmon Corp LLC
Komipharm International Co Ltd
Kura Oncology Inc
Kyowa Hakko Kirin Co Ltd
Lantern Pharma Inc
Les Laboratoires Servier SAS
Lion Biotechnologies Inc
Loxo Oncology, Inc.
Mabion SA
MacroGenics Inc
Mallinckrodt Plc
Mebiopharm Co Ltd
MedImmune LLC
Medisyn Technologies Inc
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Microlin Bio, Inc.
Millennium Pharmaceuticals Inc
Mirati Therapeutics Inc
Molecular Partners AG
MolMed SpA
Morphotek Inc
Multimmune GmbH
Mycenax Biotech Inc
NanoCarrier Co Ltd
Natco Pharma Ltd
Nektar Therapeutics
Nemucore Medical Innovations Inc
NeoPharm Co Ltd
Netris Pharma SAS
Neumedicines Inc
NewLink Genetics Corp
Northwest Biotherapeutics Inc
Novartis AG
NuCana BioMed Ltd
Omnitura Therapeutics Inc
Oncobiologics Inc
Oncogenex Pharmaceuticals Inc
Oncolys BioPharma Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Onxeo SA
Optimum Therapeutics LLC
Oribase Pharma
Oscotec Inc
OSE Immunotherapeutics
Oxford BioTherapeutics Ltd
Paranta Biosciences Ltd
Pfizer Inc
Pharma Mar SA
Philogen SpA
Phosplatin Therapeutics LLC
Pique Therapeutics
Plexxikon Inc
Polaris Pharmaceuticals Inc
ProNAi Therapeutics Inc
Provectus Biopharmaceuticals Inc
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Purdue Pharma LP
Qu Biologics Inc
Reata Pharmaceuticals Inc
Recombio SL
Rexahn Pharmaceuticals Inc
Rgenix Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Sapvax
Scancell Holdings Plc
SciClone Pharmaceuticals Inc
ScinoPharm Taiwan Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Henlius Biotech Co Ltd
Shanghai Pharmaceutical Co Ltd
Shionogi & Co Ltd
Sigma-Tau SpA
SignPath Pharma Inc
Sorrento Therapeutics Inc
Sotio as

'

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838